Acute bacterial maxillary sinusitis: results of U.S. and European comparative therapy trials.
Loracarbef, which is the first agent of the carbacephem class of beta-lactam antibiotics to be developed, provides good activity against a broad spectrum of bacteria. A single-blinded, randomized, parallel clinical trial in 10 centers in the United States compared the efficacy and safety of loracarbef with that of amoxicillin/clavulanate potassium in the treatment of acute bacterial maxillary sinusitis. A 7-10-day regimen of loracarbef (400 mg twice daily) was as effective as amoxicillin/clavulanate (500/125 mg three times a day) and resulted in somewhat fewer side effects. The results of a European trial in Sweden, Finland, and Iceland showed that loracarbef was clinically more effective than doxycycline in the treatment of acute bacterial maxillary sinusitis.
Nielsen
R W
RW
Ear, Nose, and Throat Center of Salt Lake City, Utah.
D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005387:Finland; D006801:Humans; D007055:Iceland; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D016037:Single-Blind Method; D013548:Sweden; D016896:Treatment Outcome; D014481:United States
D002511:Cephalosporins; D002969:Clavulanic Acids; C054920:loracarbef; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D004318:Doxycycline